Expression of mRNA FoxP3 in sorted CD4+CD25bright T cells before and after ASCT
. | Healthy controls . | Before ASCT . | Time after ASCT . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | 3 months . | 6 months . | 9 months . | 1 year . | 2 years . | ||||
| mRNA FoxP3 | 26.2 ± 4.7 | 12.7 ± 6.6* | 19.8 ± 5.4 | 29.2 ± 7.8† | 29.3 ± 7.8† | 36.4 ± 4.8† | 40.2 ± 15.1† | ||||
. | Healthy controls . | Before ASCT . | Time after ASCT . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | 3 months . | 6 months . | 9 months . | 1 year . | 2 years . | ||||
| mRNA FoxP3 | 26.2 ± 4.7 | 12.7 ± 6.6* | 19.8 ± 5.4 | 29.2 ± 7.8† | 29.3 ± 7.8† | 36.4 ± 4.8† | 40.2 ± 15.1† | ||||
mRNA FoxP3 expression in sorted CD4+CD25bright T cells of healthy controls and JIA patients before and after ASCT. CD4+CD25bright T cells were isolated from the PB of 3 patients who had received transplants before and at different time points after ASCT and from the PB of 3 healthy controls. mRNA FoxP3 was measured by quantitative PCR. Data are expressed as the mean normalized gene expression (± SEM).
Significant (P < .05) compared to healthy controls
Significant (P < .05) compared to the same population before ASCT